Novel Transdermal Delivery Technology
Dyve’s technology fluidizes the stratum corneum lipid matrix and modulates cellular junctions to transiently create a paracellular drug delivery pathway that leverages the body’s largest organ – the skin – as a delivery portal.
Data set in pre-clinical and human testing across a range of molecules demonstrates ability to overcome historically challenging chemical characteristics (size, solubility, lipophilicity, etc.).
PK + efficacy validation
In a pay-load and platform specific way, we’ve shown robust pharmacokinetic and efficacy benefits versus existing routes of delivery – fast, efficient, and convenient dosing that non-invasively bypasses GI challenges for local or systemic delivery.